News

The company has reported net earnings of $1.53 billion for the fourth quarter of 2008, an increase of 28%, compared to $1.20 billion posted in the fourth quarter

James S. Kuo, Cordex’s chief executive officer commented, “We are pleased to have completed our corporate name change and selected a new ticker symbol. The Cordex name was

James Kelly, CEO of Stem Cell Innovations, said: “We have been working for several years to develop a more effective method for producing stem cells from germ cells.

Ethox produces proprietary medical devices and is engaged in contract manufacturing of disposables for many medical device companies. Ethox also provides microbiology, toxicology and sterilization services. In 2006,

Through the partnership, The Leukemia & Lymphoma Society (LLS) will provide $3.7 million to support Celator’s Phase IIb multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy

In the Phase II/III trial, patients are randomly assigned to one of two treatment arms. Those allocated to the defibrotide prophylaxis arm receive 25mg/kg/day in four divided doses

The pediatric vaccine is proposed to be indicated for active immunization against invasive pneumococcal disease and middle ear infections caused by Streptococcus pneumoniae in infants and children from

This first-in-man trial is a prospective, multi-center, single blind, randomized, controlled study using the Cinatra voclosporin coated coronary stent system, which will be compared to Atrium’s Cinatra bare

According to the company, patients treated with ecabet sodium achieved a strong positive trend in the objective sign of tear film break-up time and a positive trend in